Diabetes drug may help obese and overweight people without diabetes lose weight

Embargoed until: Publicly released: 2022-10-11 02:00

Australia; International; NSW

CC:0

International researchers, including an Australian, say overweight or obese people without diabetes could potentially lose weight by taking a diabetes drug called semaglutide. The study, which was funded by the drug's manufacturer, Novo Nordisk, found the use of a once-weekly injection of the drug led to weight loss equal or greater than 5% of participants' body weight after two years, compared to a group receiving a placebo (a non-active injection). The only downside for those people receiving the drug was more frequent 'gastrointestinal adverse events' than in the placebo group, though they were mostly mild-to-moderate in intensity.

Media release

From:

Journal/
conference: Nature Medicine

Research:Paper

Organisation/s: St George Private Hospital, University of Alabama at Birmingham, USA

Funder: The study was funded by Novo Nordisk. The funder designed the trial, oversaw its conduct, monitored trial sites, and collected and analyzed the data; investigators were responsible for trial-related medical decisions and data collection. This article was drafted under the guidance of the authors, with medical writing and editorial support paid for by the funder.

Media Contact/s

Contact details are only visible to registered journalists.